We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
- Authors
Ghosn, Jade; Flandre, P; Cohen-Codar, I; Girard, P-M; Chaix, M-L; Raffi, F; Dellamonica, P; Ngovan, P; Norton, M; Delfraissy, J-F; MONARK Study Group
- Abstract
The toxicities, cost and complexity of triple combinations warrant the search for other treatment options, such as boosted protease inhibitor (PI) monotherapy. MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy with zidovudine/lamivudine and lopinavir/ritonavir in antiretroviral-naïve patients.
- Publication
HIV medicine, 2010, Vol 11, Issue 2, p137
- ISSN
1468-1293
- Publication type
Journal Article
- DOI
10.1111/j.1468-1293.2009.00752.x